NCI-Navy Medical Oncology, Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD, USA
*E-mail: gremj@mail.nih.gov
We report a 66-year-old male with a history of intra-abdominal desmoid tumor, who experienced a sustained partial response to therapy while participating in an Institutional Review Board-approved phase I clinical trial of weekly gemcitabine, infusional 5-fluorouracil (5-FU) and leucovorin. The patient originally presented in 1993 with lower back pain and was found to have an intra-abdominal desmoid tumor, which was completely resected. Two years later, an abdominal recurrence was completely resected; he received adjuvant therapy with sulindac and vitamin C for 1 year. A subsequent tumor recurrence was deemed unresectable and he received tamoxifen for a total period of 24 months before disease progression. He was then treated with vinblastine and methotrexate for nine cycles. Upon disease progression, he was referred for participation in our protocol in July 1999.
Upon enrollment, he was asymptomatic and had normal laboratory test results. A computed tomography (CT) scan was remarkable for a homogeneously enhancing mass in the left lower quadrant, which measured 14.5 x 9 cm (product 132 cm2; Figure 1A). Gemcitabine 1080 mg/m2 was administered as a 30 min infusion on days 2 and 9 of each 3-week cycle. Leucovorin 20 mg/m2 was given orally on days 1 and 8 and by i.v. push on days 2 and 9, followed by a 24-h infusion of 5-FU 2250 mg/m2 on days 2 and 9. Due to minimal toxicity, the gemcitabine dose was increased to 1300 mg/m2 at the start of cycle 4. The patient requested to change to a 2 weeks on, 2 weeks off schedule after cycle nine. Restaging studies performed every three cycles showed gradual shrinkage of the tumor. The tumor met the criteria for a partial response in May 2000 (9 x 6 cm; product 54 cm2) and the response was confirmed 4 weeks later: 9 x 5.5 cm. A restaging scan performed in August 2002 showed continued shrinkage to 5.5 x 3.0 cm (product 16.5 cm2), which represents an 88% decrease in the tumor area over a 37.3 month interval (Figure 1B). By the time of writing, the patient had received 42 cycles of therapy with minimal toxicity, except for grade 12 fatigue.
|
M. A. Wright, B. Schuler, E. Szabo & J. L. Grem*
National Cancer Institute-Navy Medical Oncology, National Naval Medical Center, Bethesda, MD, USA (*E-mail: gremj{at}mail.nih.gov)
References
1. Anthony T, Rodriguez-Bigas MA, Weber TK, Petrelli NJ. Desmoid tumors. J Am Coll Surg 1996; 182: 369377.[ISI][Medline]
2. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000; 1: 262266.[Medline]
3. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 1980; 15: 8590.[ISI][Medline]
4. Klein WA, Miller HH, Anderson M, DeCosse JJ. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 1987; 60: 28632868.[ISI][Medline]
5. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991; 68: 13841388.[ISI][Medline]
6. Poritz LS, Blackstein M, Berk T et al. Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. Dis Colon Rectum 2001; 44: 12681273.[ISI][Medline]
7. Skapek SX, Hawk BJ, Hoffer FA et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 1998; 16: 30213027.[Abstract]